Published in J Bone Joint Surg Br on January 01, 2003
Outcome of multimodality treatment of Ewing's sarcoma of the extremities. Indian J Orthop (2010) 0.80
Axial Skeletal Location Predicts Poor Outcome in Ewing's Sarcoma: A Single Institution Experience. Sarcoma (2011) 0.79
Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children's Oncology Group. Ann Surg Oncol (2016) 0.75
The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet (1999) 4.77
Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol (2001) 3.29
ISWI is an ATP-dependent nucleosome remodeling factor. Mol Cell (1999) 2.68
Does lead overload develop in hemodialysis patients? Nephron (1989) 2.52
Coding sequence and growth regulation of the human vimentin gene. Mol Cell Biol (1986) 2.34
Pyrazolo-triazoles as light activable DNA cleaving agents. Bioorg Med Chem (2000) 2.30
The DNA binding site of HMG1 protein is composed of two similar segments (HMG boxes), both of which have counterparts in other eukaryotic regulatory proteins. EMBO J (1992) 2.18
Quality of life and length of survival in advanced cancer patients on home parenteral nutrition. Clin Nutr (2002) 2.12
Cloning of the mitogen-activated S6 kinase from rat liver reveals an enzyme of the second messenger subfamily. Proc Natl Acad Sci U S A (1990) 2.09
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol (2000) 2.06
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol (2012) 1.87
Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem (1998) 1.86
Acf1, the largest subunit of CHRAC, regulates ISWI-induced nucleosome remodelling. EMBO J (2001) 1.81
Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol (1998) 1.80
Prion protein expression in different species: analysis with a panel of new mAbs. Proc Natl Acad Sci U S A (1998) 1.80
Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol (2000) 1.77
Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol (2000) 1.71
Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest (1997) 1.70
Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br (2002) 1.58
Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol (1997) 1.56
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol (1991) 1.49
Breast reconstruction: a quality measure for breast cancer care? Breast (2011) 1.48
Preoperative therapy versus immediate surgery in nonmetastatic osteosarcoma. J Clin Oncol (2003) 1.46
Selenium status, fatty acids, vitamins A and E, and aging: the Nove Study. Am J Clin Nutr (1994) 1.46
Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli. J Clin Oncol (2000) 1.45
[ General postural rehabilitation in musculoskeletal diseases: scientific evidence and clinical indications]. Reumatismo (2007) 1.44
Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol (2009) 1.44
Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol (2003) 1.42
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol (2011) 1.40
A recently developed bifacial platelet-rich fibrin matrix. Eur Cell Mater (2010) 1.40
Absolute alcohol in esophageal vein sclerosis. Gastrointest Endosc (1988) 1.40
Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy. Cancer (1989) 1.40
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.39
Construction and in vitro functional evaluation of a low-density lipoprotein receptor/transferrin fusion protein as a therapeutic tool for familial hypercholesterolemia. Hum Gene Ther (1999) 1.39
Hospital use of decontaminating mats. J Hosp Infect (2003) 1.39
Gene expression profiling in MDS and AML: potential and future avenues. Leukemia (2011) 1.38
Hmg4, a new member of the Hmg1/2 gene family. Genomics (1998) 1.37
Identification of 40 S ribosomal protein S6 phosphorylation sites in Swiss mouse 3T3 fibroblasts stimulated with serum. J Biol Chem (1993) 1.36
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol (2011) 1.36
Structural and functional analysis of a growth-regulated gene, the human calcyclin. J Biol Chem (1987) 1.36
Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer (2001) 1.34
Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet (2004) 1.33
Three cases of human herpesvirus-6 latent infection: integration of viral genome in peripheral blood mononuclear cell DNA. J Med Virol (1993) 1.32
Template-imprinted nanostructured surfaces for protein recognition. Nature (1999) 1.32
Giant-cell tumor of bone in skeletally immature patients. J Bone Joint Surg Am (1983) 1.31
Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer (2001) 1.31
Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J Biol Chem (1999) 1.30
Extraabdominal desmoid tumor. A study of 83 cases. Clin Orthop Relat Res (2000) 1.28
Antidepressant medications and osteoporosis. Bone (2012) 1.28
Different brain correlates for watching real and virtual hand actions. Neuroimage (2001) 1.28
Molecular cloning of a cDNA for a human ADP/ATP carrier which is growth-regulated. J Biol Chem (1987) 1.27
Circulating epstein-barr virus in children living in malaria-endemic areas. Scand J Immunol (2005) 1.25
Differential response of embryonic and fetal myoblasts to TGF beta: a possible regulatory mechanism of skeletal muscle histogenesis. Development (1994) 1.25
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol (2010) 1.25
Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol (2001) 1.25
Degradation of B-Myb by ubiquitin-mediated proteolysis: involvement of the Cdc34-SCF(p45Skp2) pathway. Oncogene (2000) 1.24
Activation of c-myb expression by phytohemagglutinin stimulation in normal human T lymphocytes. Mol Cell Biol (1985) 1.22
A stimulated S6 kinase from rat liver: identity with the mitogen activated S6 kinase of 3T3 cells. EMBO J (1989) 1.22
Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human peripheral blood mononuclear cells in vivo. J Med Virol (1995) 1.22